1613148-71-2

Upstream product

• 3878-55-5 methyl hydrogen succinate 

Downstream Products

• 1613148-72-3 3-(5-methyl-1-phenyl-1H-benzimidazol-2-yl)propanoic acid 
• 1613149-02-2 5-methyl-2-[2-(1-methylimidazo[1,5-a]pyridin-3-yl)ethyl]-1-phenyl-1H-benzimidazole 
• 1613149-03-3 2-[2-(imidazo[1,5-a]pyridin-3-yl)ethyl]-5-methyl-1-phenyl-1H-benzimidazole 
• 1613149-05-5 7-[2-(5-methyl-1-phenyl-1H-benzimidazol-2-yl)ethyl]imidazo[1,5-b]pyridazine 
• 1613148-73-4 5-bromo-7-[2-(5-methyl-1-phenyl-1H-benzimidazol-2-yl)ethyl]imidazo[1,5-b]pyridazine 
• 1613148-74-5 5-methyl-7-[2-(5-methyl-1-phenyl-1H-benzimidazol-2-yl)ethyl]imidazo[1,5-b]pyridazine 

Relevant academic research and scientific papers

Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability

In this study, we report the identification of potent benzimidazoles as PDE10A inhibitors. We first identified imidazopyridine 1 as a high-throughput screening hit compound from an in-house library. Next, optimization of the imidazopyridine moiety to improve inhibitory activity gave imidazopyridinone 10b. Following further structure-activity relationship development by reducing lipophilicity and introducing substituents, we acquired 35, which exhibited both improved metabolic stability and reduced CYP3A4 time-dependent inhibition.